BrainsWay Ltd. (BWAY) Q2 2025 Earnings Call Transcript

BrainsWay (NASDAQ:BWAY) reported record Q2 2025 results, with revenue up 26% year-over-year to $12.6 million and Deep TMS system shipments increasing 35%, bringing the installed base to 1,522 units. The company's recurring revenue model, driven by multiyear lease agreements, contributed to a strong 75% gross margin and a robust $62 million backlog, providing significant revenue visibility. BrainsWay subsequently raised its full-year 2025 revenue guidance to $50-$52 million. Strategic growth initiatives include the advancement of an accelerated Deep TMS protocol, submitted to the FDA for potential Q4 clearance, and new minority equity investments in mental health networks, such as the initial $5 million investment in Stella MSO, aimed at expanding market reach and patient access within the non-invasive neuromodulation sector.

Analysis

BrainsWay (BWAY) delivered a strong second quarter for 2025, reporting record revenue of $12.6 million, a 26% year-over-year increase, driven by a 35% rise in Deep TMS system shipments. The company's strategic pivot towards a recurring revenue model is proving effective, with multiyear lease agreements now accounting for approximately 70% of recent customer engagements. This has resulted in a robust remaining performance obligation of $62 million, a 25% year-over-year increase, which provides significant forward revenue visibility. Profitability remains solid, with a stable gross margin of 75% and a notable increase in net profit to $2.0 million from $0.6 million in the prior-year period. The company's financial position is exceptionally strong, ending the quarter with $78.3 million in cash and no debt. Key growth catalysts are clearly defined, including a new strategic initiative to make minority investments in mental health providers, starting with a $5 million investment in Stella MSO, which has already yielded a reported 50% increase in TMS utilization. Furthermore, the company has submitted data to the FDA for an accelerated treatment protocol that could reduce treatment time from weeks to days, with a decision anticipated in Q4 2025. In light of this performance and a healthy backlog, management has confidently raised its full-year 2025 revenue guidance to a range of $50 million to $52 million.

Key Decisions for Investors

• Given the accelerating revenue growth, expanding $62 million backlog, and raised full-year guidance, investors should view the results as a strong validation of the company's scalable recurring revenue model.
• Monitor the FDA's decision on the accelerated Deep TMS protocol, expected in Q4 2025, as an approval would represent a significant near-term catalyst with the potential to substantially increase patient adoption.
• Track the execution of the new minority investment strategy and the company's ability to secure its targeted five deals by year-end, as this represents a novel, capital-intensive approach to driving market penetration and utilization.
• Consider the company's debt-free balance sheet and strong cash position of $78.3 million as a key advantage, providing ample flexibility to fund its strategic growth initiatives without dilutive financing in the near term.